124 related articles for article (PubMed ID: 37833243)
1. A community effort in SARS-CoV-2 drug discovery.
Schimunek J; Seidl P; Elez K; Hempel T; Le T; Noé F; Olsson S; Raich L; Winter R; Gokcan H; Gusev F; Gutkin EM; Isayev O; Kurnikova MG; Narangoda CH; Zubatyuk R; Bosko IP; Furs KV; Karpenko AD; Kornoushenko YV; Shuldau M; Yushkevich A; Benabderrahmane MB; Bousquet-Melou P; Bureau R; Charton B; Cirou BC; Gil G; Allen WJ; Sirimulla S; Watowich S; Antonopoulos N; Epitropakis N; Krasoulis A; Itsikalis V; Theodorakis S; Kozlovskii I; Maliutin A; Medvedev A; Popov P; Zaretckii M; Eghbal-Zadeh H; Halmich C; Hochreiter S; Mayr A; Ruch P; Widrich M; Berenger F; Kumar A; Yamanishi Y; Zhang KYJ; Bengio E; Bengio Y; Jain MJ; Korablyov M; Liu CH; Marcou G; Glaab E; Barnsley K; Iyengar SM; Ondrechen MJ; Haupt VJ; Kaiser F; Schroeder M; Pugliese L; Albani S; Athanasiou C; Beccari A; Carloni P; D'Arrigo G; Gianquinto E; Goßen J; Hanke A; Joseph BP; Kokh DB; Kovachka S; Manelfi C; Mukherjee G; Muñiz-Chicharro A; Musiani F; Nunes-Alves A; Paiardi G; Rossetti G; Sadiq SK; Spyrakis F; Talarico C; Tsengenes A; Wade RC; Copeland C; Gaiser J; Olson DR; Roy A; Venkatraman V; Wheeler TJ; Arthanari H; Blaschitz K; Cespugli M; Durmaz V; Fackeldey K; Fischer PD; Gorgulla C; Gruber C; Gruber K; Hetmann M; Kinney JE; Padmanabha Das KM; Pandita S; Singh A; Steinkellner G; Tesseyre G; Wagner G; Wang ZF; Yust RJ; Druzhilovskiy DS; Filimonov DA; Pogodin PV; Poroikov V; Rudik AV; Stolbov LA; Veselovsky AV; De Rosa M; De Simone G; Gulotta MR; Lombino J; Mekni N; Perricone U; Casini A; Embree A; Gordon DB; Lei D; Pratt K; Voigt CA; Chen KY; Jacob Y; Krischuns T; Lafaye P; Zettor A; Rodríguez ML; White KM; Fearon D; Von Delft F; Walsh MA; Horvath D; Brooks CL; Falsafi B; Ford B; García-Sastre A; Yup Lee S; Naffakh N; Varnek A; Klambauer G; Hermans TM
Mol Inform; 2024 Jan; 43(1):e202300262. PubMed ID: 37833243
[TBL] [Abstract][Full Text] [Related]
2. Beyond the vaccines: a glance at the small molecule and peptide-based anti-COVID19 arsenal.
Nepali K; Sharma R; Sharma S; Thakur A; Liou JP
J Biomed Sci; 2022 Sep; 29(1):65. PubMed ID: 36064696
[TBL] [Abstract][Full Text] [Related]
3. The race to treat COVID-19: Potential therapeutic agents for the prevention and treatment of SARS-CoV-2.
Shagufta ; Ahmad I
Eur J Med Chem; 2021 Mar; 213():113157. PubMed ID: 33486200
[TBL] [Abstract][Full Text] [Related]
4. Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach.
Dhankhar P; Dalal V; Kumar V
J Comput Biol; 2021 Dec; 28(12):1228-1247. PubMed ID: 34847746
[TBL] [Abstract][Full Text] [Related]
5. SARS-CoV-2 Nucleocapsid Protein Is a Potential Therapeutic Target for Anticoronavirus Drug Discovery.
Royster A; Ren S; Ma Y; Pintado M; Kahng E; Rowan S; Mir S; Mir M
Microbiol Spectr; 2023 Jun; 11(3):e0118623. PubMed ID: 37199631
[TBL] [Abstract][Full Text] [Related]
6. Would the Development of a Multitarget Inhibitor of 3CL
Dos Santos Nascimento IJ; de Moura RO
Med Chem; 2023; 19(5):405-412. PubMed ID: 36221875
[TBL] [Abstract][Full Text] [Related]
7. Multi-targeting approach for nsp3, nsp9, nsp12 and nsp15 proteins of SARS-CoV-2 by Diosmin as illustrated by molecular docking and molecular dynamics simulation methodologies.
Kumar S; Sharma PP; Upadhyay C; Kempaiah P; Rathi B; Poonam
Methods; 2021 Nov; 195():44-56. PubMed ID: 33639316
[TBL] [Abstract][Full Text] [Related]
8. Host Cell Proteases Mediating SARS-CoV-2 Entry: An Overview.
Oubahmane M; Hdoufane I; Bjij I; Lahcen NA; Villemin D; Daoud R; Allali AE; Cherqaoui D
Curr Top Med Chem; 2022; 22(21):1776-1792. PubMed ID: 35894476
[TBL] [Abstract][Full Text] [Related]
9. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
10. Antiviral Drug Discovery for the Treatment of COVID-19 Infections.
Ng TI; Correia I; Seagal J; DeGoey DA; Schrimpf MR; Hardee DJ; Noey EL; Kati WM
Viruses; 2022 May; 14(5):. PubMed ID: 35632703
[TBL] [Abstract][Full Text] [Related]
11. Recent Development in Small Molecules for SARS-CoV-2 and the Opportunity for Fragment-Based Drug Discovery.
Mahato S
Med Chem; 2022; 18(8):847-858. PubMed ID: 35156586
[TBL] [Abstract][Full Text] [Related]
12. A Review of Computational Approaches Targeting SARS-CoV-2 Main Protease to the Discovery of New Potential Antiviral Compounds.
Castillo-Garit JA; Cañizares-Carmenate Y; Pham-The H; Pérez-Doñate V; Torrens F; Pérez-Giménez F
Curr Top Med Chem; 2023; 23(1):3-16. PubMed ID: 35473544
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Consensus Analysis of SARS-CoV-2 Drug Repurposing Campaigns.
Mslati H; Gentile F; Perez C; Cherkasov A
J Chem Inf Model; 2021 Aug; 61(8):3771-3788. PubMed ID: 34313439
[TBL] [Abstract][Full Text] [Related]
14. TMPRSS2 and RNA-Dependent RNA Polymerase Are Effective Targets of Therapeutic Intervention for Treatment of COVID-19 Caused by SARS-CoV-2 Variants (B.1.1.7 and B.1.351).
Lee J; Lee J; Kim HJ; Ko M; Jee Y; Kim S
Microbiol Spectr; 2021 Sep; 9(1):e0047221. PubMed ID: 34378968
[TBL] [Abstract][Full Text] [Related]
15. Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase
Elkaeed EB; Alsfouk BA; Ibrahim TH; Arafa RK; Elkady H; Ibrahim IM; Eissa IH; Metwaly AM
Antivir Ther; 2023 Oct; 28(5):13596535231199838. PubMed ID: 37669909
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 proteases PLpro and 3CLpro cleave IRF3 and critical modulators of inflammatory pathways (NLRP12 and TAB1): implications for disease presentation across species.
Moustaqil M; Ollivier E; Chiu HP; Van Tol S; Rudolffi-Soto P; Stevens C; Bhumkar A; Hunter DJB; Freiberg AN; Jacques D; Lee B; Sierecki E; Gambin Y
Emerg Microbes Infect; 2021 Dec; 10(1):178-195. PubMed ID: 33372854
[TBL] [Abstract][Full Text] [Related]
17. Iterated Virtual Screening-Assisted Antiviral and Enzyme Inhibition Assays Reveal the Discovery of Novel Promising Anti-SARS-CoV-2 with Dual Activity.
Hamdy R; Fayed B; Mostafa A; Shama NMA; Mahmoud SH; Mehta CH; Nayak Y; M Soliman SS
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445763
[TBL] [Abstract][Full Text] [Related]
18. Suite of TMPRSS2 Assays for Screening Drug Repurposing Candidates as Potential Treatments of COVID-19.
Shrimp JH; Janiszewski J; Chen CZ; Xu M; Wilson KM; Kales SC; Sanderson PE; Shinn P; Schneider R; Itkin Z; Guo H; Shen M; Klumpp-Thomas C; Michael SG; Zheng W; Simeonov A; Hall MD
ACS Infect Dis; 2022 Jun; 8(6):1191-1203. PubMed ID: 35648838
[TBL] [Abstract][Full Text] [Related]
19. Repurposing immune boosting and anti-viral efficacy of
Dinata R; Nisa N; Arati C; Rasmita B; Uditraj C; Siddhartha R; Bhanushree B; Saeed-Ahmed L; Manikandan B; Bidanchi RM; Abinash G; Pori B; Khushboo M; Roy VK; Gurusubramanian G
J Biomol Struct Dyn; 2024; 42(1):43-81. PubMed ID: 37021347
[TBL] [Abstract][Full Text] [Related]
20. Facilitating SARS CoV-2 RNA-Dependent RNA polymerase (RdRp) drug discovery by the aid of HCV NS5B palm subdomain binders: In silico approaches and benchmarking.
Elghoneimy LK; Ismail MI; Boeckler FM; Azzazy HME; Ibrahim TM
Comput Biol Med; 2021 Jul; 134():104468. PubMed ID: 34015671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
